Meropenem Inj. 250mg/500mg/1g (Injectable)

Product Description

Meropenem Injection is a penem antibacterial indicated as single agent therapy for the treatment of:

  • Complicated skin and skin structure infections (adult patients and pediatric patients ≥3 months only).
  • Complicated intra-abdominal infections (adult patients and pediatric patients ≥3 months only).
  • Bacterial meningitis (pediatric patients ≥3 months only).
  • Savior Lifetec Corporation

    • TW
    • 2015
      On CPhI since
    • 2
      Certificates
    • 250 - 499
      Employees

    Savior Lifetec Corporation

    • TW
    • 2015
      On CPhI since
    • 2
      Certificates
    • 250 - 499
      Employees

    More Products from Savior Lifetec Corporation

    • Ertapenem for Injection (Sterile Bulk) (API)

      Product Ertapenem for Injection (Sterile Bulk) (API)

      Ertapenem for Injection is a new form of Carbapenem, which can be widely used on Gram-negative and Gram-positive anaerobes and aerobic.
    • Ertapenem Inj. 1g (Injectable)

      Product Ertapenem Inj. 1g (Injectable)

      Ertapenem for Injection is a new form of Carbapenem, which can be widely used on Gram-negative and Gram-positive anaerobes and aerobic.
    • Meropenem Trihydrate  (sterile) (API)

      Product Meropenem Trihydrate (sterile) (API)

      Savior Lifetec Corporation manufactures sterile carbapenem antibiotic which includes meropenem (sterile bulk). It is a broad spectrum, beta-lactamase resistant, carbapenem antibiotic for parenteral administration. It readily penetrates through the cell wall of most gram-positive and gram-negative bacteria to reach penicillin binding protein (pbp) targets.
    • Meropenem and sodium carbonate (sterile bulk)(API)

      Product Meropenem and sodium carbonate (sterile bulk)(API)

      Savior Lifetec Corporation manufactures sterile carbapenem antibiotic which includes meropenem and sodium carbonate (sterile bulk). It is a sterile, pyrogen-free, synthetic, broad spectrum, carbapenem antibiotic for intravenous administration. It is a broad spectrum, beta-lactamase resistant, carbapenem antibiotic for parenteral administration.
    • Doripenem Inj. 500mg/250mg (Injectable)

      Product Doripenem Inj. 500mg/250mg (Injectable)

      Doripenem for Injection is a penem antibacterial indicated as single agent therapy for the treatment of:Complicated urinary tract infections (including pyelonephritis) and complicated intra-abdominal infections. 


      This is a new development CDMO project. For more detail please contact [email protected] 
    • Cetrorelix for Injection EQ 0.25mg Base/ ml (Injectable)

      Product Cetrorelix for Injection EQ 0.25mg Base/ ml (Injectable)

      Indication: Inhibition of premature LH surges

      Development Status: API registration batch: Completed  FDF development: Completed  
      FDF GMP registration batch: Q3 2022 
      FDA Status 
      DMF submission: Q4 2021 
       ANDA submission: Q1 2023 

       For more detail, please contact [email protected]
    • Ganirelix for Injection EQ 250mcg Base/ 0.5ml (Injectable)

      Product Ganirelix for Injection EQ 250mcg Base/ 0.5ml (Injectable)

      Indication: Inhibition of premature LH surges

      Development Status:  API registration batch: Completed  
      FDF development: Completed  
      CMO partner survey: In progress
      FDA Status:  DMF submission: Q4 2021  ANDA submission: TBD


      For more information, please contact [email protected]
    • Paliperidone Palmitate (Sterile bulk) (API)

      Product Paliperidone Palmitate (Sterile bulk) (API)

      Indication: Treatment of schizophrenia  

      Development Status: API registration batch: 2022.  
      FDA Status: DMF submission, estimate in 2022


      For more detail, please contact [email protected]
    • Prucalopride Tablet 1mg & 2mg

      Product Prucalopride Tablet 1mg & 2mg

      Indication: Treatment of chronic idiopathic constipation (CIC)

      Development Status: API registration batch: Q3 2021  FDF development: Q4 2021 
       FDF GMP registration batch: Q2 2022 
      FDA Status: 
       DMF submission: Q2 2022 
       ANDA submission: Q4 2022


      For more information, please contact [email protected]

    Savior Lifetec Corporation resources

    Recommended products